The global cell and gene therapy clinical trials market size was valued at USD 12.62 billion in 2025. The market is projected to grow from USD 14.61 billion in 2026 to USD 47.16 billion by 2034, exhibiting a CAGR of 15.77% during the forecast period. North America dominated the market with a 41% revenue share in 2025.
The cell and gene therapy clinical trials market is experiencing substantial growth as pharmaceutical companies, biotechnology firms, and research organizations increasingly invest in advanced treatment development. Cell and gene therapies are innovative approaches designed to treat or potentially address the underlying causes of diseases by modifying cellular functions or introducing, replacing, or altering genetic material.
Clinical trials play a critical role in evaluating the safety, efficacy, and long-term outcomes of these therapies before regulatory approval. The increasing development of treatments for cancer, rare genetic disorders, inherited diseases, and other complex conditions is creating demand for specialized clinical research services.
Unlike conventional drug trials, cell and gene therapy studies often require advanced manufacturing processes, specialized patient monitoring, complex logistics, and long-term follow-up. These requirements are increasing the need for experienced contract research organizations (CROs) that can support clinical development from early-stage research through late-stage trials.
Growing investment in biotechnology research and the development of innovative treatments is a major factor driving the cell and gene therapy clinical trials market. Pharmaceutical and biotechnology companies are expanding their clinical pipelines to investigate therapies for conditions with limited treatment options.
The development of personalized and precision medicine is also contributing to demand for specialized clinical trial services. As more candidates enter clinical development, sponsors require research partners with expertise in trial design, patient recruitment, regulatory compliance, and clinical data management.
Cell and gene therapies offer potential treatment options for certain rare and inherited diseases. These conditions may require highly specialized clinical trial designs, targeted patient recruitment, and long-term safety assessments.
The need to evaluate treatment outcomes in relatively small patient populations is encouraging sponsors to work with CROs that have experience in rare disease research and complex clinical development programs.
CROs are becoming important partners in the clinical development of cell and gene therapies. They provide services such as clinical trial management, regulatory support, site selection, patient recruitment, data management, and safety monitoring.
Outsourcing these activities can help biotechnology companies access specialized expertise and manage the operational complexity of clinical trials. The increasing number of advanced therapy programs is expected to support demand for integrated CRO services.
Digital health technologies, advanced data analytics, and decentralized clinical trial capabilities are improving the management of complex studies. These tools can support patient monitoring, data collection, and coordination among clinical research sites.
In cell and gene therapy trials, specialized logistics and patient tracking are particularly important because some treatments involve individualized manufacturing, complex administration procedures, and extended follow-up periods.
The market is being shaped by several developments in advanced therapy research and clinical trial management.